ABSTRACT: A case demonstrating the necessity of thorough death investigation processes where toxicology plays an active role is presented. A 33-year-old white man presented to the emergency room in respiratory distress after an overdose episode where he was revived on the scene by fire rescue. His condition continued to deteriorate and he expired 6 days after the initial incident. No admission specimens were available for testing; however, there were specimens drawn 4 and 5 days after the incident. Drug paraphernalia from the scene was obtained by the laboratory through collaboration with local law enforcement. Drug paraphernalia was initially tested in the laboratory and after obtaining the results, the antemortem and postmortem specimens were tested identifying mitragynine and U-47700, among other drugs. These results indicate the value in obtaining and testing drug paraphernalia, and the value of testing antemortem specimens even in the event of a delay.
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The primary role of the toxicology laboratory in a medical examiner setting is to identify and measure drugs and poisons in biological samples, and based on the findings, assist the medical examiner in determining the cause and manner of death. Oftentimes, toxicology laboratories are engaged solely in the analytical testing process and are not considered as part of the death investigation system. In Miami-Dade County, the principle philosophy of the laboratory is to practice investigative forensic toxicology, which is the use of all sources of information available (law enforcement investigation, medicolegal investigation, and autopsy findings) to better correlate the drug or toxin identified with the manner and cause of death. All medical examiner case investigation information is reviewed initially to assign the appropriate drug test panels, and it is also frequently re-evaluated during the testing process by the toxicologists involved to better understand the relevance of the test results. Incorporating and correlating all information with the test results guides the toxicologists in the interpretation. Essential in this process are ongoing discussions with the investigating medical examiner and/or investigating agency during the testing process. This case report illustrates the collaborative effort of the medicolegal investigator, medical examiner, and toxicologist in properly certifying the cause and manner of death of a decedent who experienced a terminal event at home and subsequently died 6 days later in the hospital.
Case History

Terminal Event
A 33-year-old white man arrived home from work on March 29th at approximately 8:00 pm and informed his mother that he was tired. He spent some time playing with his minor child, installed a light fixture in the kitchen area, and ate take-out from a nearby restaurant, without incident. While showering, his mother prepared his bed for sleep. After a considerable amount of time waiting, the mother went to check on the decedent's welfare. The bathroom door was locked, and she reported that she could hear the decedent snoring loudly. After knocking and getting no response, the mother entered the bathroom with a key and found the decedent seated on the ledge of the bathtub facing the toilet. He was unresponsive and his upper torso was slumped sideways with his head against the bathroom wall. There was vomit on the floor and inside the tub and the water was in the off position. The decedent was partially dressed in his pants still on, but without a shirt. An unknown powder was located next to the subject as well as multiple unknown pills.
Fire rescue arrived on the scene at 10:26 pm and found the decedent in cardiac arrest with an initial cardiac rhythm of asystole. Cardiopulmonary resuscitation was initiated along with administration of epinephrine, sodium bicarbonate, and naloxone. His pulse returned and fire rescue transported him to a local emergency room (ER), where he was admitted with respiratory distress. The arrival time was 10:50 pm.
At 11:07 pm, a second dose of naloxone along with several additional doses of sodium bicarbonate was administered at the hospital. The decedent was evaluated at 11:31 pm and had a reported Glasgow Coma Score of 3. He then vomited in the ER and was intubated to preserve his airway, sedated, and placed on a paralytic. An arterial blood gas showed worsening respiratory acidosis and hypoxemia. His initial hospital toxicology drug screen was positive for benzodiazepines and opiates. The decedent was transferred to the critical care unit for further observation and treatment with a preliminary diagnosis of cardiac arrest, acute respiratory distress, overdose, and respiratory acidosis. He was placed on IV antibiotics as a precaution against aspiration pneumonia. An electroencephalography (EEG) showed consistencies with severe diffuse brain dysfunction. The decedent started showing signs of worsening kidney injury and eventually required two hemodialysis treatments, removing 2.5 L of fluid, to improve his renal status. Several days after admission, the decedent began to spike high fevers, his kidney function continued to deteriorate, and chest x-rays showed persistent pulmonary edema. The decedent's family decided to withdraw care, and his death was pronounced on April 4th at 4:06 pm. An autopsy was completed on April 6th. Toxicology specimens were obtained at autopsy and submitted to the laboratory along with antemortem specimens drawn 4 and 5 days after hospital admission. The drug paraphernalia found at the initial scene was also transported to the laboratory for testing.
Social History
The decedent was married and had a 4-year-old child who suffers from autism. He had recently filed for divorce and requested full custody of his child as his wife was living in another state. He was currently living with his mother and son, and was anxious regarding his upcoming court date. He was not known to smoke tobacco, consume alcohol or use illegal drugs.
Medical History
The decedent suffered from hypertension, obesity and anxiety disorder. He was prescribed alprazolam, sertraline, metoprolol, and pantoprazole. There was no known history of drug abuse, and he had never expressed a desire to harm himself, or attempt to commit suicide. His mother does not believe he was suicidal as he loved his son very much and was working very hard to gain sole custody of him. When his wife was finally located, however, she stated that he was very depressed about their upcoming divorce and this could be a suicide; however, she further reiterated that there were no prior suicidal ideations or attempts.
Results/Discussion
Initially, toxicology testing was not assigned on the postmortem specimens due to the 6-day delay from the time of the incident to the date of death. Although antemortem specimens from the hospital were received in the laboratory, they were not initially considered for testing as they were drawn several days after admission. Admission specimens were not available at the time the samples were requested from the hospital because they had already been discarded; the hospital in question has a policy of discarding samples after 72 h unless otherwise requested to be retained. The samples received were antemortem blood (approximately 2.5 mL volume) and serum (approximately 1.5 mL volume) drawn on April 2nd at 2:15 am (4 days after admission) and antemortem blood (approximately 2.5 mL volume) and serum (approximately 0.5 mL volume) drawn on April 3rd at 2:15 am (5 days after admission). The antemortem blood was received in purple top tubes and the antemortem serum was received in clear top tubes. Not performing testing on postmortem and antemortem specimens with such an extensive delay in death is typical in the laboratory.
Drug Paraphernalia Testing
Through collaboration with local law enforcement, the drug paraphernalia and unknown pills impounded at the scene were transported to the laboratory for testing. Paraphernalia testing is typically not performed by postmortem toxicology laboratories; however, in cases such as the one described, the evidence can provide valuable information. The exhibits submitted included the following: a bag of unknown off-white colored powder, blue pill fragments, a round-shaped orange pill with an "AD" imprint, and a round-shaped orange pill with a "smiley face" imprint. An initial visual inspection of the paraphernalia identified the origin of the blue pill fragments as a 2 mg dose of Xanax â . In addition, the pill with the "AD" imprint was visually classified as a potential 30 mg dose of Adderall â . Even though the quality of these two pills appeared to be prescription grade, further testing was conducted to confirm their contents.
The unknown powder was analyzed by first dissolving a small amount in methanol and submitted for testing by gas chromatography mass spectrometry (GC-MS). The powder revealed a mixture of U-47700, acetylcodeine, acetaminophen, 6-monoacetylmorphine, cocaine, heroin, caffeine, papaverine, meconin, and noscapine. The testing performed on the unknown powder was strictly to identify the substances present. Based on the analytical data (chromatographic peak response), the predominant drug appears to be U-47700, however, substances are known to respond differently depending on the analytical technique used for the analysis; therefore no definitive conclusions can be drawn regarding percent composition of the drugs present. The pills were also analyzed by GC-MS subsequent to dissolving a small amount in methanol. The suspected Xanax â pill fragments were actually identified as the illicit substance, etizolam, a designer benzodiazepine. The suspected Adderall â pill was identified as the illicit substance, threo-4-fluoromethylphenidate, a synthetic analogue of methylphenidate. The pill with the "smiley face" imprint which was initially suspected to be a "molly" or a synthetic cathinone, was identified as acetylpsilocin, a synthetic hallucinogenic substance with effects similar to those of psilocin/psilocybin.
Biological Specimen Testing
Based on the drug paraphernalia results, the laboratory decided to test the earliest antemortem specimen received using a targeted analysis as opposed to a routine screening method, due to the low sample volume. Drugs were not expected to be present in this specimen due to the 4-day delay, however, the laboratory believed that identification could be possible and could provide value to the cause of death for this case. The specimen was prepared for analysis using the solid-phase extraction method detailed by Shoff, et al. (1) . A targeted screen using ultrahigh performance liquid chromatography ion trap mass spectrometry with MS n capabilities (UHPLC-Ion Trap-MS n ) was performed on the antemortem specimen extracts (1). The method utilized targeted approximately 50 opiate-based substances including fentanyl analogues. The extracts were then reanalyzed using a second more comprehensive method which targets over 900 compounds.
The antemortem blood specimen from the earliest available time (April 2nd, 2:15 am) was tested initially and found to contain medications prescribed to the decedent, drugs administered while the decedent was hospitalized, and illicit substances (Table 1) . While it was not unexpected to detect drugs that were administered by the hospital in this specimen, it was surprising to detect illicit substances in a specimen drawn 4 days after the incident, especially considering the decedent was comatose while hospitalized and thus unable to continue dosing himself. After these drugs were detected in the first antemortem specimen, the remaining antemortem specimens were tested, as well as the postmortem specimens, to see how they correlated with each other. These specimens were analyzed using the same methods as the first antemortem specimen with the results indicated in Table 1 . Worth noting is that not all substances identified in the paraphernalia were found in the antemortem samples, particularly heroin and cocaine, suggesting that the decedent may not have ingested any of the powder submitted for testing or the drugs had been completely eliminated. The identification of mitragynine in the admission specimens (and not in the unknown powder) further supports that the decedent may have ingested substances from a different bag not obtained at the scene.
Quantitative analysis for U-47700 was also completed by ultrahigh-performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS) for the specimens that still had sufficient volume remaining. The specimens were prepared in duplicate, using 0.5 mL of sample volume for each aliquot, and extracted with the same solid-phase extraction technique utilized for the targeted screen. The UHPLC-MS/MS method is specific for U-47700 and utilizes a biphenyl column with 0.1% formic acid in water and acetonitrile as the mobile phase. The total runtime for this method is 2.50 min.
Upon reviewing the results for the specimens tested, it was noticed that certain drugs were detected in particular samples but not in others. While there are many possible explanations for this, including the fact that the two hemodialysis treatments the decedent underwent occurred around the same time that the samples were drawn, the more important takeaway information is that these drugs were detected even after such an extensive delay. Also of importance is the presence of mitragynine and U-47700 in all specimens tested. The multitude of drugs identified, indicated that testing antemortem specimens, even in the situation of a delay from the time of incident, can provide invaluable information to the death investigation process.
Conclusion
Ultimately, the forensic pathologist determined the cause of death to be complications of multiple drug toxicity (U-47700 and mitragynine), and the manner of death to be an accident. Despite the presence of 6-monoacetylmorphine in the powder evidence found at the scene, it was not identified in the decedent's blood and therefore could not be attributed to the cause of death. Additionally, etizolam was identified in trace amounts in both the antemortem and postmortem specimen; however, it was not considered a participant in the overall cause of death.
U-47700 is a synthetic opioid that is considered to be 7.5 times more potent than morphine. There is very little pharmacological or toxicity data currently available for this compound. It was first developed by Upjohn in the 1970s for its analgesic and sedative effects (2) . U-47700 has been identified in thirteen postmortem cases in Miami-Dade County. Concentrations ranged from <0.05 to 16 ng/mL, with a median of 0.39 ng/mL. In all cases, U-47700 was present in conjunction with other drugs; eight cases list U-47700 in the cause of death with the majority listing the manner as an accident. The case described quantified U-47700 in two different antemortem samples (1.9 and 2.2 ng/ mL) and in one postmortem sample (0.37 ng/mL). These values fall within the historic range established by the laboratory.
Mitragynine is a plant alkaloid derived from the plant Mitragyna speciosa and is commonly known as Kratom. It is an opioid-receptor agonist and is classified as an opioid. Mitragynine is believed to show concentration-dependent effects with stimulant activity at lower concentration and depressant activity at higher concentrations (3). Mitragynine is not the only active component of Kratom; at least 20-25 other pharmacoactive alkaloids have been isolated. Mitragynine is metabolized in part to 7-hydroxymitragynine and this metabolite is thought to be around 30-60 times more potent than mitragynine and around 17 times more potent than morphine. The toxic level of mitragynine has not been established thus far in the literature (4-6). Mitragynine has been detected in approximately thirty postmortem cases in Miami-Dade County but has not been quantified yet due to the lack of a validated method. This case highlights the necessity of a thorough investigation of death, cooperation between different forensic disciplines, and for toxicology to be an active part of the death investigation process. It also highlights the importance of obtaining antemortem specimens in cases where a decedent may have been hospitalized for a period of time, and the value of testing those specimens even in cases where there is a delay between time of incident and the time when the specimen is drawn. Without a thorough death investigation, obtaining the drug paraphernalia that was impounded from the scene, or making an attempt at testing the delayed antemortem samples, the forensic pathologist would have had minimal information available to attempt to certify this death and may have ended up reaching a completely different conclusion.
